Patients who got Revita after stopping tirzepatide regained 5.1% of body weight versus 8.2% on sham, yet Fractyl shares fell as investors judged the benefit small.
Recap by typeshit. Post by PRISM MarketView on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Penn State Science says the new funding supports work that uses AI to identify synthetic peptides with potential for drug development.
Exercise advice aimed at people on GLP-1 medication, shared without further detail on the specific workouts recommended.
Loading…